Innate Pharma Stock Today
| IPHA Stock | USD 1.56 0.13 7.69% |
Performance0 of 100
| Odds Of DistressLess than 50
|
Innate Pharma is trading at 1.56 as of the 12th of December 2024, a 7.69% down since the beginning of the trading day. The stock's open price was 1.69. Innate Pharma has 50 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 12th of November 2024 and ending today, the 12th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of October 2019 | Category Healthcare | Classification Health Care |
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company was incorporated in 1999 and is headquartered in Marseille, France. The company has 80.95 M outstanding shares of which 62.95 K shares are currently shorted by private and institutional investors with about 5.63 trading days to cover. More on Innate Pharma
Moving together with Innate Stock
Moving against Innate Stock
Follow Valuation Profit Patterns Daily Balance Of Power
Check how we calculate scores
Innate Stock Highlights
| Chairman CEO | Jonathan Dickinson | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsInnate Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Innate Pharma's financial leverage. It provides some insight into what part of Innate Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Innate Pharma (IPHA) is traded on NASDAQ Exchange in USA. It is located in 117, Avenue de Luminy, Marseille, France, 13009 and employs 168 people. Innate Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 144.73 M. Innate Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 80.95 M outstanding shares of which 62.95 K shares are currently shorted by private and institutional investors with about 5.63 trading days to cover.
Innate Pharma currently holds about 123.35 M in cash with (32.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.54.
Check Innate Pharma Probability Of Bankruptcy
Ownership AllocationInnate Pharma has a total of 80.95 Million outstanding shares. Roughly 99.5 (percent) of Innate Pharma outstanding shares are held by general public with 0.5 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Innate Ownership Details
Innate Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Optiver Holding B.v. | 2024-09-30 | 86.8 K | |
| Exchange Traded Concepts, Llc | 2024-09-30 | 77.3 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 43.5 K | |
| Citadel Advisors Llc | 2024-09-30 | 21.3 K | |
| Ubs Group Ag | 2024-09-30 | 8.4 K | |
| Barclays Plc | 2024-09-30 | 307 | |
| Rhumbline Advisers | 2024-09-30 | 205 | |
| Steward Partners Investment Advisory, Llc | 2024-09-30 | 200 | |
| Millennium Management Llc | 2024-06-30 | 0.0 |
Innate Pharma Historical Income Statement
Innate Stock Against Markets
Innate Pharma Corporate Management
| Sonia MD | Chief VP | Profile | |
| Odile Belzunce | VP Operations | Profile | |
| Marc Bonneville | Founder | Profile | |
| Jean Fourni | Founder | Profile | |
| Henry MSc | Vice Communication | Profile | |
| DVM MBA | VP Founder | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.44) | Revenue Per Share 0.419 | Quarterly Revenue Growth (0.69) | Return On Assets (0.14) |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.